Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

被引：0
|
作者：
Antonio Ceriello
Anne Pernille Ofstad
Isabella Zwiener
Stefan Kaspers
Jyothis George
Antonio Nicolucci
机构：
[1] IRCCS MultiMedica,
[2] Boehringer Ingelheim Norway KS,undefined
[3] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[4] Boehringer Ingelheim International GmbH,undefined
[5] Center for Outcomes Research and Clinical Epidemiology,undefined
来源：
Cardiovascular Diabetology | / 19卷
关键词：
Type 2 diabetes; Glucose variability; Empagliflozin; Cardiovascular death;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
    Ceriello, Antonio
    Ofstad, Anne Pernille
    Zwiener, Isabella
    Kaspers, Stefan
    George, Jyothis
    Nicolucci, Antonio
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [2] Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME
    Whyte, M. B.
    Shah, S.
    McGovern, A.
    van Vlymen, J.
    Hinton, W.
    Munro, N.
    de Lusignan, S.
    DIABETIC MEDICINE, 2018, 35 : 95 - 96
  • [3] Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME
    Inzucchi, S. E.
    Fitchett, D.
    Wanner, C.
    Mattheus, M.
    George, J. T.
    Woerle, H. J.
    Zinman, B.
    DIABETIC MEDICINE, 2018, 35 : 11 - 11
  • [4] Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular (CV) death with empagliflozin? Results from EMPA-REG OUTCOME
    Inzucchi, S. E.
    Fitchett, D.
    Wanner, C.
    Mattheus, M.
    George, J. T.
    Woerle, H. J.
    Zinman, B.
    DIABETOLOGIA, 2017, 60 : S425 - S425
  • [5] Reduction in Cardiovascular (CV) Death with Empagliflozin Is Consistent across Categories of Baseline HbA1c and Change in HbA1c: Results from EMPA-REG OUTCOME
    Inzucchi, Silvio E.
    Fitchett, David
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis T.
    Woerle, Hans J.
    Zinman, Bernard
    DIABETES, 2017, 66 : A313 - A313
  • [6] Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial
    Fitchett, D.
    Inzucchi, S. E.
    Wanner, C.
    Mattheus, M.
    George, J. G.
    Woerle, H. J.
    Zinman, B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 121 - 121
  • [7] EFFECT OF EMPAGLIFLOZIN ON CARDIOVASCULAR DEATH IN SUBGROUPS BYAGE: RESULTS FROM EMPA-REG OUTCOME
    D'Emden, M.
    Fitchett, D.
    Kis, Giljanovic S.
    Woerle, H.
    Zinman, B.
    Inzucchi, S.
    NEPHROLOGY, 2016, 21 : 58 - 58
  • [8] Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG Outcome
    Ridderstrale, Martin
    Toural, Elvira
    Fitchett, David
    Kis, Sanja Giljanovic
    Woerle, Hans J.
    Mattheus, Michaela
    Zinman, Bernard
    Inzucchi, Silvio E.
    DIABETES, 2016, 65 : A289 - A290
  • [9] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Toural, E.
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. -J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S. E.
    DIABETOLOGIA, 2016, 59 : S539 - S540
  • [10] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1192 - 1192
12345